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Sphingolipids, ubiquitous membrane lipids in eukaryotes, carry out a myriad of critical cellular functions. The
past two decades have seen significant advances in sphingolipid research, and in 2010 a first sphingolipid
receptor modulator was employed as a human therapeutic. Furthermore, cellular signaling mechanisms
regulated by sphingolipids are being recognized as critical players in metabolic diseases. This review
focuses on recent advances in cellular and physiological mechanisms of sphingolipid regulation and how
sphingolipid signaling influences metabolic diseases. Progress in this area may contribute to new under-
standing and therapeutic options in complex diseases such as atherosclerosis, diabetes, metabolic syn-
dromes, and cancer.Sphingolipid Metabolism and Signaling
Sphingolipids are eukaryotic specific lipids that carry out essen-
tial structural and functional roles (van Meer and Hoetzl, 2010).
Within membranes sphingolipids are found associated with
cholesterol, and together they help form lipid domains. Thus
sphingolipids are necessary for the formation of specialized
membrane domains such as rafts and caveolae.
De Novo Sphingolipid Biosynthetic Pathway
All eukaryotic cells have the capacity to produce sphingolipids
via a de novo pathway in the endoplasmic reticulum (Bartke
and Hannun, 2009). In this pathway, the amino acid serine is
conjugated with the fatty acid palmitoyl CoA by the rate-limiting
enzyme serine palmitoyl transferase (SPT). The product of the
reaction, dihydrosphingosine (sphinganine), is further converted
to dihydro ceramide, which is dehydrogenated into ceramide,
a key intermediate. Specialized carrier proteins such as ceram-
ide transfer protein (CERT) transport ceramide to the Golgi. Ce-
ramide can follow several metabolic fates. For example, it can be
glycosylated to form glycosphingolipids, phosphorylated into
ceramide 1-phosphate, or acquire a polar head group to form
sphingomyelin. SM and glycosphingolipids are stable, accumu-
late to high levels in cells, and are transported via vesicle-
mediated mechanisms to specialized membrane domains. For
example, sphingomyelin accumulates in the outer leaflet of the
plasma membrane as a major constituent of rafts (Figure 1).
The control of sphingolipid synthesis by cells is regulated by
substrate availability as well as by other mechanisms related to
lipid composition and membrane homeostasis (Bartke and Han-
nun, 2009; Breslow and Weissman, 2010). The availability of
the substrate palmitoyl CoA enhances the de novo synthesis
of sphingolipids. Since free palmitate levels rise in obesity
and metabolic excess, sphingolipid flux through the de novo
pathway is enhanced (Bikman and Summers, 2011; Holland
and Summers, 2008). Recently, the Orm family proteins, which
inhibit the SPT enzymes, were found to control de novo sphingo-
lipid synthesis (Breslow et al., 2010) in the yeast S. cerevisiae.
When sphingolipid levels are low, Orm proteins are highly
phosphorylated by the protein kinase Ypk1, a yeast homolog
of the mammalian serum and glucocorticoid-induced kinase.420 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.This modification blocks the ability of the Orm proteins to inhibit
SPT enzyme complex in the ER and therefore enhances de novo
sphingolipid synthesis (Roelants et al., 2011). Interestingly, Ypk1
kinase itself is activated by the protein kinase called target of
rapamycin complex (TORC) 2 that can sense the membrane
sphingolipid levels, especially ceramide (Aronova et al., 2008;
Dickson, 2008). Recently, it was shown that sphingolipid deple-
tion or plasmamembrane stress in yeast (induced bymechanical
stretching) activated translocation of the Slm1 protein to the
Torc2 complex, activation of Torc2-dependent Ypk1 kinase,
phosphorylation of Orm proteins, and stimulation of sphingolipid
synthesis via SPT. It is thought that increased sphingolipids
reduce membrane stress, and thus this system represents a
homeostatic regulatory system for cellular membranes (Berch-
told et al., 2012) (Figure 2). Whether this signaling system regu-
lates sphingolipid synthesis in vertebrates and metazoans is
not known, but interestingly, regulation of the mTorc2-depen-
dent Akt kinase (which is in the same AGC kinase family as the
yeast Ypk1) is regulated by biomechanical forces in a caveo-
lae-dependent manner (Yu et al., 2006).
In mammalian cells, ceramide transport via the CERT protein
also is sensitive to intracellular sphingolipid levels, which appear
to regulate CERT function by PKD-dependent phosphorylation
(Kumagai et al., 2007). Therefore, cells appear to possess the
machinery to couple membrane sphingolipid levels to the bio-
synthetic pathway at the level of the rate-limiting enzyme SPT
as well as at other key regulatory steps. However, it is important
to stress that our knowledge of regulation of sphingolipid metab-
olism is significantly limited compared to other lipid regulatory
pathways, i.e., sterol metabolism.
Sphingomyelinase Pathway-Derived Mediators
An extensive network of enzymes metabolize sphingolipids
into bioactive lipid mediators (Milhas et al., 2010) (Figure 1).
For example, sphingomyelinase, which responds to extracellular
signals, forms ceramide via a hydrolytic reaction. Ceramide is
further converted to sphingosine by ceramidases. Sphingosine
levels in cellular membranes are kept low in part due to the action
of ceramide synthase and sphingosine kinases (Sphk1 and
Sphk2), which phosphorylate it into sphingosine 1-phosphate
Figure 1. Sphingolipid Metabolism
Key intermediates are boxed, and enzymes are shown in green highlights. Key steps of regulation are indicated with asterisks. *: regulation at the step at the rate-
limiting enzyme SPT. Please refer to Figure 2 for details. **: ceramide transport from the ER to the Golgi needs the CERT protein, which is subject to regulation by
cellular signaling pathways. ***: intracellular S1P is secreted by the Spns2 transporter to mediate its extracellular actions on S1P receptors. Intracellular S1P is
a key intermediate in the formation of phospholipids (via phosphoethanolamine) and triglycerols (via palmitoyl CoA).
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by specific transporters, one of which, spinster 2 homolog-2
(Spns2), was recently characterized (Kawahara et al., 2009).
In mammalian plasma, high levels of S1P are found, whereas
interstitial fluids contain very low levels, thus forming a gra-
dient of S1P in different compartments (Pappu et al., 2007)
(Figure 3A). Both hematopoietic cells and vascular endothelial
cells contribute to high plasma S1P (Pappu et al., 2007; Venka-
taraman et al., 2008), and lymphatic endothelial cells (Pham
et al., 2010) are thought to secrete S1P for the lymphatic circula-
tion. Acute liver failure strongly suppresses plasma S1P levels
(Yong-Moon Lee and T.H., unpublished data). Further, produc-
tion of HDL-associated ApoM, which chaperones S1P (see
below) by the liver, may be important for high plasma S1P (Chris-
toffersen et al., 2011). The action of Spns2 in vascular endothe-lium is important for maintaining high plasma S1P, as global
knockout as well as endothelial-specific knockout of Spns2 re-
sulted in significant decreases in plasma S1P (Fukuhara et al.,
2012). ABCC1 was proposed to be the S1P transporter in mast
cell lines (Mitra et al., 2006); however, Abcc1 knockout mice
did not show alterations in plasma S1P levels (Lee et al., 2007).
Thus, whether ABCC1 is a physiologically relevant S1P trans-
porter is unclear and themechanismbywhich S1P is transported
from hematopoietic cells remains unknown. Since ABC transport
inhibitors are nonspecific, much of the conclusions on S1P trans-
port by this class of membrane proteins should be reassessed
using more specific tools and/or genetic models.
HDL and Other S1P Chaperones
Plasma S1P is bound to HDL (65%) and albumin (30%). Inter-











Figure 2. Regulation of SPT Enzyme in S. cerevisiae
Membrane tension changes or sphingolipid depletion leads to translocation of
Slm1 protein and activation of TORC2 complex. This leads to increased
activity of the Ypk1 kinase, which phosphorylates the ORM complex and thus
relieves the inhibitory activity of the SPT enzyme. This results in increased de
novo synthesis of sphingolipids.
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is dependent on S1P (Nofer et al., 2004; Sattler and Levkau,
2009). These studies suggest that the beneficial property of
HDL to reduce the risk of cardiovascular disease may in part
depend on its S1P chaperoning function. The molecular details
of how HDL carries S1P was elusive until recently. Apolipopro-
tein M (ApoM) binds to S1P (KD 1 mM), cocrystallizes with
S1P, delivers S1P to its receptors, and is essential for S1P
association with HDL in both mice and humans (Christoffersen
et al., 2011). In Apom KO mice, endothelial barrier function
was compromised even though significant plasma S1P was still
present, associated with other plasma proteins such as albumin.
It is currently unclear how HDL/ApoM complex interacts with cell
surface S1P and HDL receptors. It is likely that S1P and HDL
receptors cooperate upon HDL interaction with cell surfaces.
In contrast to S1P, ceramide in plasma is associated mostly
with VLDL and LDL (Khovidhunkit et al., 2004). In addition, glyco-
sphingolipids are also associated with LDL and VLDL (Nilsson
and Duan, 2006). The role of lipoprotein-associated sphingoli-
pids in normal cardiovascular function and pathology is not
well understood. It is likely that enrichment of sphingolipids in
lipoproteins and cardiovascular cells contributes to the high
abundance of S1P in the circulatory system.
S1P Catabolic Routes
S1P is degraded by several enzymes. S1P phosphatases-1 and
-2 as well as lyso phospholipid phosphatase 3 (LPP3) and S1P
lyase are involved in the degradation of this lipid mediator (Blaho
and Hla, 2011; Bre´art et al., 2011) (Figure 1). The phosphatases
convert S1P into sphingosine and thus feed back into the
sphingolipid metabolic pathway. However, S1P lyase irreversibly
degrades it into hexadecenal and phosphoethanolamine (Saba422 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.et al., 1997), which are intermediates in the phospholipid biosyn-
thetic pathway. Recent work shows that further conversion of the
highly reactive fatty aldehyde hexadecenal into hexadecenoic
acid by hexadecenal dehydrogenase occurs inmany cells. Since
this ubiquitous pathway ultimately leads to the formation of
palmitoyl CoA, it is important for conversion of sphingolipids
to glycerolipids (Nakahara et al., 2012). Further details of S1P
metabolism can be obtained in the following recent authoritative
reviews: Bartke and Hannun, 2009; Bre´art et al., 2011; Cyster
and Schwab, 2012; Maceyka et al., 2012.
Receptor-Dependent Signaling of S1P
Although all eukaryotes, from single-celled yeast to complex
multicellular organisms, possess the entire sphingolipid meta-
bolic pathway, the extracellular appearance of S1P and its
receptor-dependent signaling modes seem to be vertebrate
specific (Blaho and Hla, 2011). Indeed, S1P transporter and its
G protein-coupled receptors are only present in the vertebrate
genomes. There are five receptors for S1P, named as S1P1–
S1P5. These receptors are closely related to lysophosphatidic
acid and cannabinoid receptors and are encoded by five distinct
genes (Hla and Brinkmann, 2011; Hla et al., 2001). They are
expressed widely and couple to overlapping as well as distinct
G proteins. Receptor signaling, cellular effects, and biological
effects have been extensively discussed in several recent review
articles (Blaho and Hla, 2011; Chun et al., 2010; Hla and Brink-
mann, 2011; Maceyka et al., 2012). Most cells express one or
more subtypes of S1P receptors. Therefore, S1P has multiple
biological effects in various organ systems.
The most well-characterized effects of S1P are on vascular
and immune systems (Blaho and Hla, 2011; Cyster and Schwab,
2012; Obinata and Hla, 2012). In the vascular system, S1P acti-
vation of its receptors regulates vascular tone, vascular perme-
ability, angiogenesis, vascular hyperplasia after injury, athero-
sclerosis, and heart function. However, in the immune system,
the S1P gradient is critical for egress of immune cells from
secondary lymphoid organs into the circulatory system. There-
fore, S1P receptor-dependent trafficking paradigms are critical
for normal immune homeostasis as well as inflammatory situa-
tions that occur in autoimmune diseases. A unique aspect of
S1P signaling is that the ligand is present in abundance for the
cardiovascular and blood-borne cells (Hla et al., 2008; Schwab
et al., 2005). Given that the dissociation constants of ligand
receptor interactions are in the low nanomolar range (Hla et al.,
2001; Lee et al., 1998), it is likely that cell surface receptors would
be stimulated when exposed to plasma (total concentration of
S1P in plasma is approximately 0.5–1 mM). Therefore, receptor
expression and subcellular localization are key to bioactivity of
S1P signaling in cells (Oo et al., 2011). Thus, a given cell with
S1P receptors on the plasma membrane will receive a more
robust intracellular signal than the cell in which the receptors
are sequestered in intracellular organelles.
Recently, an S1P receptor modulator called Fingolimod/
Gilenya was approved for the treatment of multiple sclerosis in
over 40 countries (Brinkmann et al., 2010). It is a functional
antagonist of the S1P1 receptor, by inducing irreversible inter-
nalization into endosomes, which makes the lymphocytes
refractory to the S1P-dependent egress step from lymphoid
organs. Thus, Fingolimod treatment leads to disrupted traf-
ficking of autoreactive T cells and suppression of autoimmune
Figure 3. S1P Gradients and Lymphocyte
Trafficking
(A) S1P gradients. Plasma is enriched in S1P due
to synthesis by red blood cells, endothelial cells,
and the liver, which provides ApoM, the physio-
logical S1P carrier on HDL. Sixty-five percent of
plasma S1P is carried by ApoM in HDL, whereas
the remainder is largely associated with albumin.
Lymph contains 20% of plasma S1P, which is
contributed by lymphatic endothelial cells. In
contrast, S1P in tissue interstitial fluids is kept low,
in part due to the high activity of degradative
enzymes such as the S1P lyase. The formation of
S1P gradients is critical in its physiological actions
in immune and vascular systems.
(B) Immune cell egress and S1P gradients. In
lymph nodes and other secondary lymphoid
organs, low S1P environment allows surface
presentation of S1P1 receptor, which is necessary
for lymphocyte egress. High S1P in lymph and low S1P in the lymph node are needed for efficient egress. However, the LPP3 lipid phosphatase (Bre´art et al.,
2011) and S1P transporter Spns2 (Fukuhara et al., 2012) may allow microgradients of S1P at the nexus of lymphatic endothelium and lymphocytes.
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entered the clinical era, and numerous efforts are being under-
taken to further understand the biology of this lipid signaling
pathway and to develop novel therapeutics in the control of
various autoimmune and related diseases.
How Do Intracellular Sphingolipids Influence Cell
Behavior?
Sphingolipid metabolism under normal cellular homeostasis is
thought to be critical for fundamental cellular events such as
membrane homeostasis, endocytosis, cell movement, nutrient
transport, and protein synthesis (Hannun and Obeid, 2008; Bre-
slow andWeissman, 2010). In addition, extracellular stimuli such
as cytokines, hormones, and cell stress (X-ray, UV irradiation)
perturb sphingolipid metabolism via effects on both de novo
synthesis and degradation (Gault et al., 2010; Morales et al.,
2007; Stancevic and Kolesnick, 2010; Zeidan and Hannun,
2010). This results in localized increases in ceramide levels.
This hydrophobic sphingolipid induces aggregation of lipid
domains and forms ceramide-rich macrodomains. Such do-
mains are large (from >200 nm to several microns in diameter)
and are thought to influence membrane signaling events as
described below (Cremesti et al., 2001; Grassme´ et al., 2003).
Since lipid rafts localize signaling proteins, it is likely that ceram-
ide-induced formation of macrodomains would alter composi-
tion, clustering, and interaction of signaling proteins and/or
lipids. Thus, alterations in ceramide levels likely influence lipid/
lipid, protein/lipid, and protein/protein interactions within the
membranes translating to transmission of intracellular signals.
Further, it has been shown that ceramide can interact with
a number of signaling proteins, such as kinase suppressor of
ras (KSR), atypical protein kinase-C (Yin et al., 2009; Zhang
et al., 1997), c-Raf-1 (Basu et al., 1998), cathepsin D (Pettus
et al., 2002), and ceramide-activated protein phosphatase (Chal-
fant et al., 2004; Dobrowsky et al., 1993). The physiological sig-
nificance of such interactions remains to be further explored. In
other words, it is not clear if such interactions occur in a classi-
cal second messenger mode, whereby lipid/protein interaction
changes the activity and/or localization of a particular signaling
protein. However, it is likely that membrane domain perturba-
tions induced by changes in ceramide levels profoundly alterthe recruitment and/or composition of signaling proteins at a
membrane locale. In some cases, alteration of ceramide content
of specific organelle membranes may lead to biologically signif-
icant events. For example, the increase in ceramide levels in the
mitochondria is associated with apoptosis (Deng et al., 2008;
Lee et al., 2011; Siskind et al., 2002). Thus, recent data support
the model by which ceramides influence cellular signaling by
membrane-intrinsic events (Figure 4). This viewpoint has re-
placed the classical second messenger mode of action of
ceramide, in which ceramide interacts with soluble proteins
outside of membrane compartments.
In addition to ceramide, sphingosine, which is produced by
ceramidase, is also capable of altering cellular signaling reac-
tions. It binds to the 14-3-3 protein isoforms, regulates their
phosphorylation at the dimer interface, and inhibits the antiapop-
totic functions of 14-3-3 (Woodcock et al., 2003, 2010). In addi-
tion, sphingosine binds directly to the ANP32a and ANP32b
proteins, which inhibit the protein phosphatase PP2A (Habruko-
wich et al., 2010). Increases in the intracellular levels of sphingo-
sine or N,N’-dimethylsphingosine block the ability of ANP32
proteins to inhibit PP2A and thereby increase the activity of
this key protein phosphatase. In addition, sphingosine binds to
the nuclear receptor steroidogenic factor (SF1) and inhibits the
transcription of genes such as CYP17 (Urs et al., 2006, 2007).
Indeed, in structural studies, sphingosine is found in the ligand
binding pocket of SF1 (Li et al., 2005; Sablin et al., 2009). These
studies support the concept that intracellular sphingosine levels,
which are determined by the activities of ceramidase and sphin-
gosine kinases, may fluctuate under various physiological condi-
tions and regulate a myriad of cellular functions. However, it is
not clear at present whether sphingosine levels play a critical
role in the regulation of metabolic reactions as was shown for
ceramide (Figure 4).
Some studies have suggested that S1P has intracellular
actions (Spiegel et al., 1996; Spiegel and Milstien, 1995). Early
studies suggested that intracellular S1P regulated calcium
transients (Ghosh et al., 1990, 1994); however, no molecular
entity was identified that could mediate intracellular S1P action
to modulate calcium transients. Several studies have also
suggested the role of intracellular S1P in the regulation of cell
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Figure 4. Mechanism of Action of Sphingolipid Mediators
Ceramide is thought to act via alteration of membrane domains and signaling
intermediates such as PP2A, resulting in the inhibition of the protein kinase Akt.
The ability of sphingosine to directly bind to 14-3-3, ANP32a, and the nuclear
transcription factor SF1 may also be involved in cellular regulation. S1P is
secreted by specific transporters such as Spns2 into the extracellular envi-
ronment where it accumulates to high levels in plasma. S1P binds to and
activates five G protein-coupled receptors (S1P1–S1P5).
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2003; Van Brocklyn et al., 1998). However, two recent studies by
the Spiegel laboratory have identified the TNF-a signaling inter-
mediate, TRAF2 (Alvarez et al., 2010), and the nuclear factor
histone deacetylase HDAC1 and 2 (Hait et al., 2009) as S1P
binding molecules whose activities are modulated by binding
to this sphingolipid. In the case of TRAF2, sphingosine kinase-
1-derived S1P was reported to interact with and modulated its
ubiquitin ligase activity. For HDAC1 and HDAC2, sphingosine
kinase-2-derived S1P inhibited their catalytic activity. Since
S1P signals through the cell-surface G protein-coupled recep-
tors, which can influence both cytosolic and nuclear changes,
the significance of these intracellular interactions are unclear.
However, it is established that S1P (and dihydroS1P) play a crit-
ical metabolic function by serving as an intermediate in the
biosynthesis of important building blocks of phospholipid
synthesis, namely, fatty aldehydes, which are subsequently con-
verted into fatty acyl CoAs and phosphoethanolamine (Nakahara
et al., 2012). This metabolic function is thought to be important
in membrane homeostasis (Dobrosotskaya et al., 2002).
Extracellular Signaling of Sphingosine 1-Phosphate
It is now established that extracellular S1P signals via its five
GPCRs to regulate numerous organ systems (Blaho and Hla,
2011). Signaling properties of the S1P receptors are well charac-
terized, and some physiological roles of S1P have been eluci-
dated by the analysis of mutant mice for receptors as well as
the use of pharmacological tools (Chun et al., 2010). Some of
the known biological processes regulated by S1P appear to be424 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.important in normal cellular handling of nutrients, and thus dys-
regulated S1P signaling could contribute to metabolic disease.
As a corollary, S1P-regulated cellular and physiological events
could play critical roles in metabolic syndromes.
S1P and Immune Cell Trafficking
The ability to regulate immune cell trafficking could be impor-
tant in obesity-associated inflammation. It is known that S1P
is essential for the egress of lymphocytes from thymus and
secondary lymphoid organs as well as the re-entry of lympho-
cytes into peripheral lymphatics from tissue interstitium (Cyster
and Schwab, 2012). In that scenario, high concentrations of
S1P found in lymph, as well as local gradients established by
reticuloendothelial system of egress portals, activate the S1P1
receptor on lymphocytes and regulate successful extravasation
(Figure 3B). At the cellular level, lymphocytes appear to dynam-
ically sample the environment with cellular protrusions and
interact with resident reticuloendothelial cells. Given that the
S1P1 receptor avidly induces Gi-dependent Rac activation, Akt
phosphorylation, cortactin translocation, microtubule dynamics,
and F-actin assembly (Hla et al., 2001), it is likely that such
GPCR-induced membrane protrusion events are necessary for
efficient egress to occur. Analysis of T cell egress from lymph
nodes also suggested that the balance of two competing
chemokine signaling events determines egress rates. One sig-
naling event, e.g., the balance between CXCL21 and CCR7,
promotes T cell retention, whereas the other, e.g., S1P/S1P1,
promotes egress (Grigorova et al., 2009; Pham et al., 2010).
Since hematopoietic cells in various environments, such as the
bone marrow, spleen, lymph node, tissue interstitial spaces,
and inflammatory milieu, are exposed to numerous chemokine
and lipid mediator gradients, competition between different
GPCR signaling systems likely influences the cellular behavior
and the likelihood of retention versus egress. In addition, S1P-
mediated signaling may play a role in the cellular arrangements
into specific tissue architectures. For example, it is known that
S1P2 receptor activates the G12/13 pathway to stimulate Rho
GTPase, resulting in the activation of PTEN, increased cAMP
levels, and inhibition of Akt and Rac GTPase (Michaud et al.,
2010; Sanchez et al., 2005, 2007; Windh et al., 1999). These
events result in reduced cell motility. Since the S1P2 receptor
is critical for increased macrophage content in atherosclerotic
plaques (Skoura et al., 2011) and the ability to commit B cells
to germinal centers (Green et al., 2011), cellular aggregation/
dispersion events, which ultimately determine lymphoid archi-
tecture, may also be regulated.
Such mechanisms could play important roles in obesity-asso-
ciated inflammation in adipose tissue. For example, increased
infiltration of CD8 T cells and inflammatory macrophages could
result from S1P receptor-driven processes (Nishimura et al.,
2009). Further, tissue retention of circulating hematopoietic pro-
genitor cells and their differentiation into myeloid lineage (Mass-
berg et al., 2007) could further enhance monocyte/macrophage
content of adipose tissues. The appearance of clusters of
macrophages, commonly referred to as ‘‘crown-like structures’’
in adipose tissue of obese animals and humans (Morris et al.,
2011), could also be regulated by S1PR-regulated events. The
role of such migratory and collective cellular architectures may
be important in dysregulated inflammatory reactions seen in
metabolic syndromes and obesity-related disorders.
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S1P signaling is also critical for vascular development and
homeostasis. S1P1–S1P3 receptors play significant roles in
endothelial and vascular smooth muscle cells (Hla et al., 2001).
In vascular smooth muscle, S1P2 and S1P3 regulate vasocon-
striction, presumably due to the coupling to Gq/IP3/Ca
2+ and
G12/13/Rho/ROCK signaling pathways (Kono et al., 2007; Mura-
kami et al., 2010; Salomone et al., 2003; Szczepaniak et al.,
2010). In contrast, coupling of S1P1 in endothelial cells to the
eNOS enzyme, presumably due to Gi/PI3K/Akt pathway, results
in endothelium-dependent vasorelaxation (Dantas et al., 2003;
Igarashi and Michel, 2009; Nofer et al., 2004). Thus, modula-
tion of S1PRs can contribute to local vascular tone and sys-
temic changes in blood pressure. Whether this plays a role in
obesity-associated hypertension is not known. In the endo-
thelium, S1P1 signaling is critical for VE-cadherin-dependent
adherens junction assembly and regulation of vascular perme-
ability (Jacobson and Garcia, 2007; Lee et al., 1999; McVerry
et al., 2004; Sanchez et al., 2003). Regulation of cell-matrix
interactions through strengthening of integrin-mediated events
also plays a role in this phenomenon (Paik et al., 2001). In con-
trast, S1P2 promotes vascular permeability, due to its ability
to induce Rho-dependent cell rounding and disruption of cell-
cell junctions (Sanchez et al., 2007; Skoura et al., 2007). Interest-
ingly, S1P2 mRNA is induced under hypoxic and inflammatory
conditions. The ability to control vascular permeability by S1P
receptors suggests that dysregulation of this system could
participate in obesity-associated inflammatory conditions.
Indeed, increased vascular permeability is an essential feature
of inflammation.
S1P receptors regulate vascular development and angiogen-
esis (Liu et al., 2000; Paik et al., 2004). In obesity, concomitant
with adipocyte hypertrophy and hyperplasia, increased neovas-
cular growth or angiogenesis occurs. This is in fact essential
since tissue growth and concomitant increases in oxygen and
metabolic demands must be met by increased vascular supply.
The ability of S1P1 to cooperate with angiogenic growth factors
and stabilize neovessels (Lee et al., 1999) is likely critical in this
context. Other S1P receptors, namely S1P2 and S1P3, cooperate
with S1P1 in embryonic angiogenesis (Kono et al., 2004). It is not
known what the consequences are of S1PR dysfunction in
obesity-associated angiogenesis.
Does S1P Influence Thrombosis and Hemostasis?
In addition to the S1P ligand released by activated platelets,
presumably during thrombotic episodes (Yatomi, 2006), S1P
signaling in the endothelial cells also appears to regulate throm-
bosis and hemostasis (Obinata and Hla, 2012). Activated protein
C binds to its receptor and transactivates the S1P1 receptor to
maintain the barrier function of the endothelium (Finigan et al.,
2005). In addition, thrombin activation of its receptor PAR-1
results in S1P secretion and autocrine activation of S1P1
receptor, which allows the recovery of the barrier dysfunction
(Komarova et al., 2007). The role of S1P and its receptors in
thrombosis, hemostasis, and fibrinolysis are not well under-
stood. However, given the crosstalk between inflammatory,
angiogenic, and clotting pathways (Obinata and Hla, 2012), it is
highly likely that S1P signaling in endothelial cells and platelets
regulate such processes. During obesity, thrombotic episodes
increase, and factors that promote thrombosis as well as inhibitfibrinolysis increase. Whether S1P signaling and sphingolipid
metabolic alterations play a role in such pathophysiologic
scenarios needs further investigation.
S1P and the Pancreas
Endodermal organs such as the pancreas develop in response to
intrinsic transcriptional cues, as well as endothelial- and blood-
derived signals. Blood-derived S1P appears to be one such
factor (Cleaver and Melton, 2003). Pancreatic mesenchymal
bud development in the mouse is regulated by blood-derived
S1P, which acts on its receptors to regulate organ development
and differentiation (Edsbagge et al., 2005; Serafimidis et al.,
2011). Furthermore, concomitant vascular development and
endothelial cell signaling also regulate pancreatic development
by both delivery of oxygen and nutrients as well as angiocrine
signaling. In the adult, pancreatic b cell survival and response
to cytokines appear to be modulated by S1P receptors
(Laychock et al., 2006; Ru¨tti et al., 2009). In murine models,
S1P2 receptor appears to mediate b cell cytotoxicity, whereas
HDL activation of S1P receptors appears to attenuate inflamma-
tory cytokine-induced b cell loss.
In addition to these events, signaling of S1P receptors in
adipocytes, muscle, liver, and heart likely also regulates meta-
bolic pathways and thus influences the pathophysiology of
obesity and metabolic syndromes. However, specific mecha-
nisms and biological effects remain poorly understood at
present. A brief summary of S1P receptor functions in metabolic
conditions is given in Table 1.
Sphingolipids in the Control of Glucose Homeostasis
Recent work shows that increased levels of saturated fatty
acids such as palmitate (16:0) result in the increased metabolic
flux into the de novo sphingolipid biosynthetic pathway (Bikman
and Summers, 2011; Samad et al., 2011; Yang et al., 2009).
Therefore, in obesity and metabolic syndromes, increased levels
of sphingolipids, in particular, ceramide, are observed. Second,
activation of TLR4 by saturated fatty acids results in the
upregulation of ceramide synthetic enzymes in an IkBb kinase-
dependent manner (Holland et al., 2011a). The net result is the
increased levels of ceramide in various cellular membranes,
which are associated with profound insulin resistance. The
importance of this pathway is established in studies that show
that inhibition of de novo sphingolipid synthesis by myriocin,
an inhibitor of SPT, reversed the insulin resistance observed in
murine models of obesity (Holland et al., 2007). Additionally,
studies in myocytes cultured in vitro have shown that ceramide
rather than sphingosine is responsible for fatty acid-mediated
attenuation of insulin-stimulated glucose uptake and Akt phos-
phorylation (Chavez et al., 2005). These data point to the critical
role of ceramide in metabolic dysregulation of glucose uptake
and metabolism.
This was further underscored in a recent study that showed
that adiponectin, a key homeostatic hormone, acts on its recep-
tors in adipocytes, cardiacmuscle, and liver to convert increased
ceramide levels to S1P (Holland et al., 2011b). Adiponectin
receptors induce ceramidase enzyme activity by a poorly under-
stoodmechanism resulting in the formation of S1P via a sphingo-
sine kinase-dependent pathway. This is important for reducing
insulin resistance, cardiac dysfunction, and liver pathologies
associated with obesity and metabolic dysregulation.Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc. 425
Table 1. Regulation of Physiological Processes by S1P Receptor Subtypes









T cells S1P1R Lymphocyte egress,
phenotype switching
Immune response, inflammation Liu et al., 2010; Cyster and
Schwab, 2012
B cells S1P2R Germinal center architecture Humoral immune response Green et al., 2011
Macrophages S1P1R Anti-inflammatory
M2-like response
Innate immune response Hughes et al., 2008




Skoura et al., 2011




Lee et al., 1999;
Nofer et al., 2004
Endothelial cells S1P2R Adherens junction disassembly Vascular inflammation Sanchez et al., 2007;
Skoura et al., 2007
Vascular smooth
muscle cells
S1P3R, S1P2R Vasoconstriction Hypertension Salomone et al., 2003;
Murakami et al., 2010
Pancreatic b cells S1P1R Insulin secretion, islet survival Normal glucose homeostasis Laychock et al., 2006;
Fukuhara et al., 2012
Multiple S1P receptors in different cell types regulate various biological processes that have an impact in metabolic diseases. Some relevant examples
from preclinical models are summarized.
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As discussed above, ceramide levels inmembranes greatly influ-
ence lipid domain structure and dynamics. Indeed, large macro-
domains of membranes are formed when ceramide levels rise
(Cremesti et al., 2002; Gulbins and Kolesnick, 2003). Further-
more, using cell culture models in which exogenous ceramide
was introduced, it was found that translocation of Akt to plasma
membrane via its PH domain was inhibited (Stratford et al.,
2001). Moreover, activation of protein phosphatase PP2A
(Dobrowsky et al., 1993), which can attenuate Akt signaling,
was observed. Thus, increased ceramide levels likely block
insulin signaling by antagonizing the key signaling intermediate
Akt, which is needed for stimulation of glucose transport
as well as downstream transcriptional responses. It is also
likely that additional steps are involved in various organelle
membranes of the cell, via biophysical mechanisms as well as
by modulation of key signaling intermediates.
In addition to ceramide, increased sphingolipid biosynthesis
could lead to the activation of Sphk enzymes and the production
of S1P. Extracellular S1P can modify function and survival of
pancreatic b cells in the islets. Treatment of isolated islets with
HDL or S1P resulted in increased survival. In contrast, LDL
induced increased islet apoptosis. Thus, extracellular S1P can
influence insulin levels (Ru¨tti et al., 2009). Indeed S1P enhanced
survival of pancreatic islet cells in vitro (Laychock et al., 2006).
Furthermore, S1P treatment acutely increases insulin secretion
from pancreatic b cell lines and in isolated islets in vitro (Fuku-
hara et al., 2012). It is not known if systemic S1P or local
increases in S1P production, which can be induced by glucose
via the activation of Sphk1 (Mastrandrea et al., 2010), is involved
in physiological control of insulin secretion.
Although considered more as structural components of cell
membranes, glycosphingolipids also play important roles in
insulin sensitivity. Increased levels of glycosphingolipids, which
are found in genetic disorders of glycosphingolipid breakdown426 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.such as Gaucher’s disease, are associated with resistance to
insulin signaling as manifested by reduced insulin-stimulated
glucose uptake (Aerts et al., 2011; Inokuchi, 2010). Although
the mechanisms involved are not entirely clear, insulin receptor
is inhibited by high glycosphingolipid microenvironment of
the plasma membrane. Indeed, the ganglioside GM3 seems to
directly associate with the insulin receptor and inhibits down-
stream signaling. Reduction of glycosphingolipid levels by
inhibitors of synthesis, treatment with degrading enzymes, or
knockout of biosynthetic enzymes in mouse models reversed
insulin resistance, suggesting an important role for this family
of sphingolipids (Aerts et al., 2011; Inokuchi, 2010). However,
the relationships between ceramide- and glycosphingolipid-
induced insulin resistance are not well understood. Whether
they represent parallel systems or are interconnected is not clear
at present. In addition, tissue specificity (i.e., muscle versus
adipose tissue) of ceramide versus glycosphingolipid functions
could also determine the overall pathophysiological state of
insulin resistance.
These findings indicate that sphingolipids influence glucose
metabolism in a variety of tissues. In metabolic syndrome,
where abnormal lipid accumulation is seen in nonadipogenic
tissues such as liver, muscle, heart, and pancreas (Holland and
Summers, 2008), increased sphingolipid levels likely play pro-
found pathophysiological roles.
Sphingolipids at the Crossroads of Amino Acid, Fatty
Acid, and Carbohydrate Metabolism
The rate-limiting enzyme in the sphingolipid biosynthetic path-
way, SPT, is an oligomeric enzyme composed of three SPTLC
subunits. SPTLC2 and SPTLC form heterodimers, which have
low enzymatic activity, but upon association with the third
subunit, called ssSPT, greatly enhanced activity was seen. It is
thought that heterotrimeric SPT isozymes or higher-order oligo-
meric structures are functional (Lowther et al., 2012). Mutations
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neuropathy called hereditary sensory autonomic neuropathy
type I (HSAN1) (Garofalo et al., 2011). Interestingly, such muta-
tions changed the property of this rate-limiting enzyme: in
addition to reducing the catalytic efficiency, substrate promis-
cuity was observed, resulting in the formation of abnormal
sphingolipids. The mutant enzymes used alanine and glycine
as atypical substrates and produced abnormal sphingolipids:
deoxysphinganine and deoxymethylsphinganine, respectively
(Gable et al., 2010). These sphingolipids lack the hydroxyl group
at C1 and cannot be converted into phosphorylated and glycosy-
lated complex sphingolipids. In addition, degradation enzymes
including S1P lyase and phosphatases cannot metabolize these
deoxysphingolipids. However, they can be N-acylated into
ceramides and oxidized into sphingosines by the introduction
of the trans double bond at C4-C5.
Since free sphingoid bases or ceramides can induce cell
stress responses, and similar deoxysphingolipids isolated
from marine sponges induce cellular toxicity, it was hypothe-
sized that the formation of deoxysphingolipids causes neuronal
toxicity in HSAN1 (Garofalo et al., 2011; Scherer, 2011). Indeed,
Merrill and colleagues found that deoxysphingolipids were
formed by treatment of cells or mice with fumonisin B1, which
inhibits ceramide synthase (Zitomer et al., 2009). In fact, utiliza-
tion of alanine by wild-type SPT occurs to a degree that results
in the formation of abnormal sphingolipids. Fumonisin B1, by
inhibiting the conversion of such sphingoid bases into ceramide
species, enabled the formation of deoxysphingolipids to be
readily detected (Zitomer et al., 2009). However, by altering sub-
strate availability, i.e., supplementation of L-serine, the formation
of deoxysphingolipids was suppressed in a transgenic model of
HSAN1 (C133W SPTLC1 mutant mouse) and in human HSAN1
patients. In the mouse, L-serine supplementation suppressed
symptoms of neuropathy and male reproductive abnormalities,
suggesting the pathogenic role of abnormal deoxysphingolipids
(Garofalo et al., 2011).
Since the precursors of deoxysphingolipids are naturally
occurring amino acids, such as alanine and glycine, which are
coupled to carbohydrate metabolic pathways (e.g., glycolysis),
it is likely that altered levels of amino acids, which occurs in
metabolic syndrome and diabetes, would lead to alterations in
deoxysphingolipid levels. This was shown by the laboratory of
Hornemann, who examined the levels of deoxy and 1-hydroxyl-
ated sphingolipids in normal subjects and in patients with
metabolic syndromes and diabetes (Bertea et al., 2010; Othman
et al., 2012). They found significant upregulation of glycine- and
alanine-derived sphingolipids in plasma of diabetics and meta-
bolic syndrome patients compared to controls. These data are
exciting because deoxy-sphingoid bases were enriched in the
LDL and VLDL fractions in the plasma and could serve as useful
biomarkers in metabolic syndromes. Furthermore, they could
play a role in the pathogenesis of diabetic neuropathy as well
as in other changes, including microvascular alterations.
Future studies need to focus on cellular and molecular mech-
anisms, which mediate the cytotoxic reactions of the deoxy-
sphingolipids. They can be present as free sphingoid base or
as ceramides and thus could alter intracellular signaling path-
ways by interacting with specific downstream signaling proteins
or alteration of membrane structure. This would allow novelapproaches to reverse the pathologic phenotypes associated
with deoxysphingolipids.
Sphingolipid Metabolic Connections with Cellular Lipid
Hemeostasis
Sphingolipid metabolism is tightly coupled to other lipid
metabolic pathways, for example, sterol metabolism (Degroote
et al., 2004). Changes in plasma membrane sphingomyelin
results in major alterations in cellular cholesterol levels and traf-
ficking, presumably due to the affinity of these two lipids. Thus, it
was observed that sphingomyelinase treatment of cells, which
reduces plasma membrane sphingomyelin, resulted in the in-
creased levels of free cholesterol in the ER (Scheek et al.,
1997; van Meer and Hoetzl, 2010). This was shown to inhibit
the activation of SREBP-1, thus resulting in the inhibition of
cholesterol synthesis and uptake, primarily by the downregula-
tion of HMG CoA reductase and LDL-R expression. Similarly,
enhanced uptake of sphingomyelin resulted in trapping of sphin-
golipids and cholesterol in late endosomes and lysosomes, thus
reducing free cholesterol at the ER, and increased SREBP-medi-
ated upregulation of cholesterol synthesis and uptake. Thus,
sphingolipid and cholesterol metabolic pathways are tightly
linked, which raises further questions about the consequences
of such interactions in metabolic diseases such as atheroscle-
rosis and diabetes.
Sphingolipid synthesis and breakdown appear to be critical
for feedback control of phospholipid synthesis in Drosophila,
in which SREBP pathway senses levels of phosphatidyl entha-
nolamine (PE) (Dobrosotskaya et al., 2002). The de novo sphin-
golipid biosynthetic pathway is coupled to PE synthesis by
providing the fatty acid substrate. When phosphorylated sphin-
goid bases are degraded, fatty acid aldehydes and phosphoe-
thanolamine are produced by the S1P lyase reaction. Such
intermediates are necessary for PE synthesis. Indeed, PE levels
are sensed by SREBP, which in turn controls the sphingolipid
biosynthetic enzymes. Whether this mechanism occurs in verte-
brates is not known, but this example illustrates the interconnec-
tions that exist between cellular lipid metabolic systems.
Recent studies in S. cerevisiae suggest a novel feedback
control of sphingolipid biosynthesis involving TORC2 and Orm
proteins (Aronova et al., 2008; Roelants et al., 2011; Tabuchi
et al., 2006). Analysis of TORC2 subunit Avo3 (yeast homolog
of the mammalian RICTOR) showed that TORC2 kinase controls
ceramide levels. Specifically, TORC2 activates the Ypk2 kinase,
which is necessary for the activity of ceramide synthase enzyme.
Previous studies by the laboratories of Dickson (Dickson, 2008)
and Kozutsumi (Sun et al., 2000) have shown that sphingosine
and similar long-chain bases activate the Ypk2 kinase in
a Phk1 and Phk2 kinase-dependent manner. This constitutes
a feed-forward regulatory loop whereby reduced ceramide syn-
thase activity leads to increased sphingosine and activation of
Ypk2 and ceramide synthesis in a TORC2-dependent manner.
In another study, activation of Ypk2 and TORC2 phosphorylated
the Orm proteins and inhibited their repression of SPT activity
(Breslow and Weissman, 2010; Roelants et al., 2011). Thus,
Ypk2/TORC2 pathway increases sphingolipid synthesis by acti-
vating ceramide synthase and SPT activity. Since TORC2 is an
evolutionarily conserved pathway regulated by nutrient avail-
ability, cell growth, and cellular energy status (Laplante andCell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc. 427
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connected with sphingolipid pathways highlights the potential
importance of these lipids in cellular metabolic regulation. The
universality of this paradigm needs to be further explored.
Inflammation Impact on Sphingolipids
During inflammatory processes,mobilization of innate and adap-
tive immune cells to the tissues as well as activation of cytokine
networks ensues. Such changes are regulated by sphingolipids,
and sphingolipid metabolism is altered in tissues as a response
to these alterations. The trafficking of both naive and activated
adaptive immune cells is regulated by S1P signaling via the
S1P receptor-1 (Cyster and Schwab, 2012). In addition, dendritic
and NK cell trafficking is also regulated, even though other S1P
receptors such as S1P5 may be involved. Thus, S1P signaling is
required for proper trafficking patterns, which ensure the optimal
magnitude and duration of both humoral and cellular immune
responses. Evidence also exists for the regulation of cellular
phenotype by S1PR signaling. Thus, the regulatory T cells
(Treg), which are very important to attenuate inflammatory and
autoimmune responses, is regulated by the S1P1/Akt/mTOR
signaling axis (Liu et al., 2010). In multiple sclerosis patients
who were administered the S1PR modulator Fingolimod, levels
of circulating TH17 cells (which promote inflammatory reactions)
is reduced, whereas Treg numbers increase, suggesting that
such changes underlie the efficacy of this pharmacological agent
(Mehling et al., 2010). Whether S1P/S1PR signaling controls
myeloid cell influx, survival, and egress is not known. However,
macrophages express significant levels of the mRNA for S1P1
and S1P2. S1P1 function is associated with anti-inflammatory
or M2 phenotype (Hughes et al., 2008), whereas S1P2 inhibits
the chemokine-induced migration of macrophages to tissue
spaces (Michaud et al., 2010). In addition, S1P2 function in
macrophages appears to regulate the number of macrophages
that infiltrate the atherosclerotic plaques in mouse models,
perhaps due to its ability to reduce chemokine-induced motility
and thereby block egress (Skoura et al., 2011). Further studies
are needed to define the role of S1P receptors in obesity-
induced inflammatory responses.
S1PRs in endothelial cells could also play a role in driving
the extent and intensity of the inflammatory response in tis-
sues. In vitro studies have shown that S1P1 and S1P2 exert
opposing roles in regulating vascular permeability (Sanchez
et al., 2007; Skoura and Hla, 2009). In addition, S1P2 mRNA
expression appears to be induced in pathological states. Thus,
by regulating plasma exudation, tissue inflammatory responses
could be altered. It is known that deposition of plasma pro-
teins such as fibrin into the interstitial spaces would induce an
acute inflammatory response, since fibrin degradation products
have profound effects on innate immune cells (van Hinsbergh,
2012). Whether S1P-regulated vascular changes play a role in
obesity-associated inflammatory responses warrants further
investigation.
In contrast to the well-established roles of extracellular S1P/
S1PR signaling in various biological responses, the intracellular
role of sphingolipids in inflammatory reactions is equivocal and
its physiological role unclear. Even though sphingolipid turnover
is stimulated by innate immune stimulation, for example, TNF-a
signaling (Peraldi et al., 1996; Dressler et al., 1992), whether428 Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc.this is essential for the ability of the cytokine to function is not
clear. Ceramide formation is induced in many systems, but its
duration varies and may be related to membrane changes that
occur secondary to cytokine action. Importantly, coimmunopre-
cipitation of the TNF-a effector TRAF2 with Sphk1 was observed
in transfected cells (Xia et al., 2002). In addition, a recent report
suggested that Sphk1-derived intracellular S1P is a cofactor for
the E3 ubiquitin ligase activity of TRAF2 and that this interaction
is necessary for TNF-a-induced NF-kB activation (Alvarez et al.,
2010). This interesting report was based entirely on in vitro find-
ings. However, in our recent study of Sphk1 and Sphk2 double-
KO macrophages, TNF-a-induced NF-kB responses are indis-
tinguishable fromWTmacrophages, suggesting that intracellular
S1P is not essential for the TNF-a-induced inflammation in these
cells (Yuuan Xiong and T.H., unpublished data). Further, Sphk1
(Michaud et al., 2006) and Sphk2 mice (Zemann et al., 2007)
exhibit normal inflammatory responses, and a recent report
that claimed the essential role of Sphk1 in mouse models of
sepsis (Puneet et al., 2010) was highlighted as potentially of
ethical concern by the journal Science (Alberts, 2011), which rai-
ses serious questions about the conclusions in that paper, which
implied the critical role of Sphk1 in sepsis.
S1P, abundantly expressed in the vascular compartment, is an
important player in maintaining normal homeostasis. However,
its proper function may be required in the regulation of extent,
intensity, and duration of inflammatory reactions. Its mode of
action is clearly different from classical lipid mediators such as
eicosanoids, which are produced upon demand and act rapidly
to regulate inflammatory reactions (Shimizu, 2009). Whether
compartment-specific function of S1P regulates inflammation
requires further study. As such, it could be critical in obesity-
associated inflammatory responses.
Potential Involvement of Sphingolipids
in Obesity-Associated Syndromes
Atherosclerosis
Sphingolipids play complex roles in initiation and progression of
atherosclerosis, a disease that causes the highest morbidity and
mortality in developed and newly developing countries. Plasma
sphingomyelin levels were correlated with incidence of cardio-
vascular disease even though this finding has not been univer-
sally confirmed (Chen et al., 2011; Jiang et al., 2000; Schlitt
et al., 2006; Yeboah et al., 2010). Importantly, inhibition of SPT
withmyriocin reduced plasma sphingomyelin levels and reduced
atherosclerotic lesions in murine models of atherosclerosis (Hoj-
jati et al., 2005). These data suggest that sphingolipid metabolic
alterations could play important roles in atherosclerosis.
In related studies, SMS2 enzyme, which synthesizes sphin-
gomyelin, was shown to play important roles in atherosclerosis
(Liu et al., 2009a, 2009b). Deletion of the Sms2 gene resulted
in attenuation of plasma sphingomyelin level and reduced
plaque burden in mouse models of atherosclerosis. Studies in
macrophages suggest that SMS2 is required for the elevation
of sphingomyelin and diacylglycerol, two lipids that are impor-
tant for raft formation and PKC activation, respectively. Indeed,
TLR2-induced NF-kB activation was impaired in Sms2 KO cells
(Hailemariam et al., 2008), suggesting that attenuated inflam-
matory mechanisms may explain the antiatherogenic pheno-
type.
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regulate is the aggregation and retention of LDL and VLDL in
the subendothelial space. Tabas and coworkers showed that
secreted acid sphingomyelinase acts in LDL and VLDL to induce
their aggregation, which is presumably mediated by the produc-
tion of ceramide (Schissel et al., 1998). This event may cause
increased uptake of aggregated lipoproteins by resident macro-
phages and their differentiation into foam cells. Thus, acid
sphingomyelinase KO mice exhibited a profound reduction in
atherosclerotic lesion formation (Devlin et al., 2008).
Given that increased sphingolipid entry and breakdown
occurs in inflamed vascular wall, presumably due to the influx
of proatherogenic lipoproteins and increased expression of
secreted sphingomyelinases during inflammation (Tabas et al.,
2007), it is likely that downstream sphingolipid mediators are
also enhanced. In that context, we hypothesized that increased
S1P in the vascular lesions would signal via S1P receptors to
regulate atherosclerotic plaque progression. S1p2rKO exhibited
profound reduction in plaque area in both LDLR and ApoE
models of atherosclerosis (Skoura et al., 2011). Indeed, the func-
tion of S1P2 in macrophages seems to be important. Possible
mechanisms include retention of macrophages in the plaque
by the antimigratory S1P2 receptor and themodulation of inflam-
matory phenotype (secretion of proinflammatory cytokines such
as IL-1b and IL-18). Another study on S1p3r KOmice showed its
importance in macrophage influx without alterations in athero-
sclerotic plaque size (Keul et al., 2011). However, S1P1 and
S1P2 are expressed at higher levels in macrophages and likely
play more prominent roles in atherosclerosis in mouse models
(Michaud et al., 2010). The effect of S1P1 in atherosclerosis
has not been addressed in animal models. However, in vitro,
S1P1 is necessary for the induction of the anti-inflammatory
M2 phenotype (Hughes et al., 2008). The interplay of S1P recep-
tors in endothelial cells, macrophages, and vascular smooth
muscle cells likely plays important roles in initiation and progres-
sion of atherosclerosis. Since sphingolipids are critical in this
vascular disease, further knowledgewill likely provide novel ther-
apeutic opportunities in this challenging area of translational
research.
Cancer
Sphingolipids play myriad and profound roles in cancer. For
example, dietary sphingolipids suppress colon carcinogenesis
in animal models (Merrill et al., 1995). Sphingosine kinases are
elevated in numerous cancer models and are being actively
pursued as a therapeutic target given that knockout of Sphk1
enzyme suppresses intestinal polyposis in mouse genetic
models (Kohno et al., 2006). The reader is referred to the fol-
lowing recent reviews, which address this issue in a comprehen-
sive manner: Cuvillier, 2007; Fyrst and Saba, 2010; Pitson, 2011;
Pyne and Pyne, 2010. The focus of our discussion will be how
metabolic alterations in the sphingolipid signaling axis that occur
in obesity have the potential to impact cancer development and
progression.
Obesity is an established risk factor for numerous malignan-
cies (Calle and Kaaks, 2004). In addition to being a risk factor
for the development of postmenopausal breast cancer, obesity
is associated with an increased risk of cancers of the colon,
esophagus, endometrium, kidney, and pancreas (van Kruijsdijk
et al., 2009). Moreover, obesity is increasingly recognized asa poor prognostic factor for many malignancies (Yoon et al.,
2011). Several mechanisms appear to account for the link
between obesity and carcinogenesis. Increased production of
estrogen in excess adipose tissue has been suggested to con-
tribute to the increased risk of postmenopausal breast cancer
(Cleary and Grossmann, 2009). Multiple lines of evidence sup-
port a role for obesity-related effects on insulin levels and the
insulin-like growth factor-1 axis, in addition to altered production
of adipokines in the pathogenesis of cancer (van Kruijsdijk et al.,
2009). Obesity also causes increased levels of proinflammatory
mediators, which may impact on the development and progres-
sion of cancer (Olefsky and Glass, 2010; Sinicrope and Dannen-
berg, 2011).
Given the link between obesity and cancer, it is worth con-
sidering whether sphingolipid alterations could be involved.
Cancer development and progression are accelerated by the
proinflammatory microenvironment, as exemplified in Helico-
bacter pylori-induced gastric cancer and hepatitis B-induced
liver cancer, among others. Indeed, obesity causes systemic
as well as local inflammation, including increased myeloid cell
infiltration, presence of crown-like structures of macrophage
aggregates, and increased proinflammatory cytokine produc-
tion (Morris et al., 2011; Subbaramaiah et al., 2011). Since
increased levels of ceramide and S1P modulate immune and
inflammatory reactions, signaling of sphingolipids could con-
tribute to the pro-oncogenic microenvironment. For example,
increased S1P signaling in endothelial cells could induce angio-
genesis and thereby induce tumor growth and metastasis.
Recruitment of various types of immune cells in the tumor
microenvironment could also be regulated by S1P signaling.
For example, myeloid-derived suppressor cells are known to
suppress antitumor immunity (Lindenberg et al., 2011), and
whether trafficking or differentiation of such cells is regulated
by S1P receptor signaling warrants investigation. In addition,
membrane sphingomyelin and ceramide levels are known to
be critical for antigen presentation and raft-dependent T cell
receptor function (Levental et al., 2010). Systemic alterations
in ceramide levels, which are seen in obesity, could be in-
volved in suppression of cell-mediated immunity against tumor
antigens.
The provision of the inflammatory milieu in general could
involve dysregulated sphingolipid signaling. Indeed, increased
S1P1 signaling in tumor cells via the Stat3 pathway was shown
to be critical for tumor development and metastasis in mouse
models (Lee et al., 2010). S1P2 receptor is involved in regulation
of tumor cell migration and angiogenesis (Lepley et al., 2005;
Li et al., 2008, 2011). Thus, the role of sphingolipids in obesity-
induced protumorigenic microenvironment warrants further
investigation.
Summary
Sphingolipid alterations occur in obesity and metabolic dis-
eases. Importantly, specific sphingolipid signaling pathways,
which influencemajor biological processes such as insulin sensi-
tivity, lipid metabolism, inflammation, and immune reactions, are
dysregulated. New knowledge on the biology of sphingolipids is
anticipated to enhance our understanding of metabolic diseases
and obesity-associated conditions. Furthermore, it is likely that
this area will prove fertile in the search for new therapeutic
targets to control obesity and associated maladies.Cell Metabolism 16, October 3, 2012 ª2012 Elsevier Inc. 429
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